Sunshine Biopharma's ROE % for the quarter that ended in Mar. 2026 was -22.34%. Sunshine Biopharma's PB Ratio for the quarter that ended in Mar. 2026 was 0.24.
Sunshine Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -93.08%.
Sunshine Biopharma ROE % Adjusted to Book Value Related Terms
Sunshine Biopharma ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma ROE % Adjusted to Book Value Chart
SBFM vs PRFX, CTTH, CVSI: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -93.08% mean?
Sunshine Biopharma (SBFM) has a ROE % Adjusted to Book Value of -93.08% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sunshine Biopharma and its competitors.
Is Sunshine Biopharma's ROE % Adjusted to Book Value too high?
Sunshine Biopharma's current ROE % Adjusted to Book Value is -93.08%. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's ROE % Adjusted to Book Value compare to PRFX and CTTH?
Sunshine Biopharma's ROE % Adjusted to Book Value of -93.08% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current ROE % Adjusted to Book Value is -93.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.17 — trading 69.4% below its estimated fair value. The current ROE % Adjusted to Book Value is -93.08%. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current ROE % Adjusted to Book Value is -93.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $2.17 is trading 69.4% below its estimated GF Value™ of $7.10.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
ROE % Adjusted to Book Value: -93.08%
GF Value™: $7.10 vs. price of $2.17 (69.4% below fair value)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
